Response to Letter to the Editor From Shaorong Yu and Jifeng Feng
- PMID: 38185512
- DOI: 10.1016/j.jtho.2023.10.018
Response to Letter to the Editor From Shaorong Yu and Jifeng Feng
Comment on
-
Comment on "Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial".J Thorac Oncol. 2024 Jan;19(1):173-174. doi: 10.1016/j.jtho.2023.08.013. J Thorac Oncol. 2024. PMID: 38185511 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources